{
    "clinical_study": {
        "@rank": "70376", 
        "arm_group": [
            {
                "arm_group_label": "Haloperidol", 
                "arm_group_type": "Active Comparator", 
                "description": "Haloperidol 5mg intramuscular injection"
            }, 
            {
                "arm_group_label": "Valproate", 
                "arm_group_type": "Active Comparator", 
                "description": "Valproate single Infusion; 400 mg (weigh<60 kg), 500 mg (weight>60 Kg)"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to compare the efficacy of haloperidol and valproate in management\n      of people with agitation in emergency department"
        }, 
        "brief_title": "Haloperidol vs. Valproate in Agitation", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Psychomotor Agitation", 
        "condition_browse": {
            "mesh_term": "Psychomotor Agitation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of psychomotor agitation\n\n          -  aged 18 to 65 years\n\n        Exclusion Criteria:\n\n          -  Pregnant patients\n\n          -  Severe liver disease\n\n          -  History of drug (haloperidol/valproate) allergy\n\n          -  Readily amendable causes for the agitation (hypoxemia or hypoglycemia)\n\n          -  Hypotension (systolic blood pressure (SBP) \u2264 90 mm Hg)\n\n          -  Known history of liver disease or uncontrolled diabetes\n\n          -  Noticeable or suspected head trauma\n\n          -  Previous history of neuroleptic malignant syndrome\n\n          -  Receiving psychotropic medication, neuroleptic agents or cholinesterase inhibitors at\n             the time of enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01750541", 
            "org_study_id": "SB-021", 
            "secondary_id": "MOH-021"
        }, 
        "intervention": [
            {
                "arm_group_label": "Haloperidol", 
                "intervention_name": "Haloperidol", 
                "intervention_type": "Drug", 
                "other_name": "Haldol"
            }, 
            {
                "arm_group_label": "Valproate", 
                "intervention_name": "Valproate", 
                "intervention_type": "Drug", 
                "other_name": "Depakene"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Valproic Acid", 
                "Haloperidol", 
                "Haloperidol decanoate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tehran", 
                    "country": "Iran, Islamic Republic of", 
                    "zip": "1617763141"
                }, 
                "name": "Department of Emergency Medicine, Imam Hossein Hospital"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Haloperidol vs. Valproate in the Management of Agitated Patients Presenting to the Emergency Department: A Randomized Clinical Trial", 
        "overall_official": {
            "affiliation": "Department of Emergency Medicine, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.", 
            "last_name": "Kamran Heydari, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Iran: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Patients were rated before medication administration and within 30 minutes afterwards according to Agitated Behavior Scale (ABS) score. Any statistically significant change in ABS score consider as positive effect of either intervention.", 
            "measure": "Reduction in Agitated Behavior Scale (ABS) score", 
            "safety_issue": "Yes", 
            "time_frame": "within the first  30 minutes of treatment onset"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01750541"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shaheed Beheshti Medical University", 
            "investigator_full_name": "Dr. Kamran Heydari", 
            "investigator_title": "Assistant Professor of Emergency Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Shahid Beheshti Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shahid Beheshti Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}